1. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer. (January 2017) Authors: Wang, Ruliang; Zhang, Shaohua; Jiang, Zefei; Tian, Jizheng; Wang, Tao; Song, Santai Journal: Clinical and experimental pharmacology and physiology Issue: Volume 44:Number 1(2017:Jan.) Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. (November 2018) Authors: Campone, Mario; Im, Seock-Ah; Iwata, Hiroji; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiełło-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Cortés, Javier; De Laurentiis, Michele; Arteaga, Carlos L.; Jiang, Zefei; Jonat, Walter; Le... Journal: European journal of cancer Issue: Volume 103(2018) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 7 (July 2017) Authors: Baselga, José; Im, Seock-Ah; Iwata, Hiroji; Cortés, Javier; De Laurentiis, Michele; Jiang, Zefei; Arteaga, Carlos L; Jonat, Walter; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiełło-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Taka... Journal: Lancet oncology Issue: Volume 18:Issue 7(2017:Jul.) Page Start: 904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. (December 2022) Authors: Zhou, Jinmei; Wu, Xuexue; Zhang, Huiqiang; Wang, Xiaobo; Yuan, Yang; Zhang, Shaohua; Jiang, Zefei; Wang, Tao Journal: Breast Issue: Volume 66(2022) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Issue 7 (July 2015) Authors: Hurvitz, Sara A; Andre, Fabrice; Jiang, Zefei; Shao, Zhimin; Mano, Max S; Neciosup, Silvia P; Tseng, Ling-Min; Zhang, Qingyuan; Shen, Kunwei; Liu, Donggeng; Dreosti, Lydia M; Burris, Howard A; Toi, Masakazu; Buyse, Marc E; Cabaribere, David; Lindsay, Mary-Ann; Rao, Shantha; Pacaud, Lida Bubuteish... Journal: Lancet oncology Issue: Volume 16:Issue 7(2015:Jul.) Page Start: 816 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China. (10th August 2017) Authors: Li, Jianbin; Wang, Shusen; Wang, Yongsheng; Wang, Xiaojia; Wang, Haibo; Feng, Jifeng; Zhang, Qingyuan; Sun, Tao; Ouyang, Quchang; Yin, Yongmei; Liu, Yinhua; Geng, Cuizhi; Yan, Min; Jiang, Zefei Journal: Oncologist Issue: Volume 22:Number 11(2017) Page Start: 1333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. Issue 1 (24th May 2020) Authors: Liu, Jieqiong; Liu, Qiang; Li, Ying; Li, Qian; Su, Fengxi; Yao, Herui; Su, Shicheng; Wang, Quanren; Jin, Liang; Wang, Ying; Lau, Wan Yee; Jiang, Zefei; Song, Erwei Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer. Issue 8 (20th March 2014) Authors: Hu, Xichun; Zhang, Jian; Xu, Binghe; Jiang, Zefei; Ragaz, Joseph; Tong, Zhongsheng; Zhang, Qingyuan; Wang, Xiaojia; Feng, Jifeng; Pang, Danmei; Fan, Minhao; Li, Jin; Wang, Biyun; Wang, Zhonghua; Zhang, Qunling; Sun, Si; Liao, Chunmei Journal: International journal of cancer Issue: Volume 135:Issue 8(2014:Oct. 15) Page Start: 1961 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Issue 8 (September 2019) Authors: Luo, Yang; Li, Wei; Jiang, Zefei; Zhang, Qingyuan; Wang, Liwei; Mao, Yixiang; Tjan-Heijnen, Vivianne C.G.; Im, Seock-Ah; McConnell, Robin; Bejarano, Sara; Fumagalli, Debora; Bines, José; Wang, Bei; Garg, Amit; Kirschbrown, Whitney P.; Xu, Binghe Journal: Anti-cancer drugs Issue: Volume 30:Issue 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study. (2nd September 2021) Authors: Guo, Fengzhu; Yi, Zongbi; Wang, Wenna; Han, Yiqun; Yu, Pei; Zhang, Su; Ouyang, Quchang; Yan, Min; Wang, Xiaojia; Hu, Xichun; Jiang, Zefei; Huang, Tao; Tong, Zhongsheng; Wang, Shusen; Yin, Yongmei; Li, Hui; Yang, Runxiang; Yang, Huawei; Teng, Yuee; Sun, Tao Journal: Cancer medicine Issue: Volume 10:Number 19(2021) Page Start: 6744 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗